Sarepta Therapeutics (SRPT) Posts Q1 Loss of 75c/Share

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.75), $0.05 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $6.09 million versus the consensus estimate of $3.45 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• SpaceX shares gain as lock-up fears ease
• Loar Holdings Inc. (LOAR) Reports Q2 EPS of $0.38 ; Offers Guidance
• Freedom Broker Upgrades The Honest Co. (HNST) to Buy